| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
14 analysts have shared their evaluations of Legend Biotech (NASDAQ:LEGN) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 6 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 3 | 1 | 0 | 0 | 0 |
| 2M Ago | 3 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 4 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $84.07, a high estimate of $87.00, and a low estimate of $65.00. Observing a 10.62% increase, the current average has risen from the previous average price target of $76.00.
A clear picture of Legend Biotech's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mitchell Kapoor | HC Wainwright & Co. | Lowers | Buy | $86.00 | $87.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $87.00 | - |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $87.00 | - |
| George Farmer | Scotiabank | Maintains | Sector Outperform | $65.00 | $65.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $87.00 | - |
| Rick Bienkowski | Cantor Fitzgerald | Announces | Overweight | $82.00 | - |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $87.00 | - |
| Ashwani Verma | UBS | Raises | Buy | $81.00 | $76.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $87.00 | - |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $87.00 | - |
| Sean McCutcheon | Raymond James | Announces | Outperform | $86.00 | - |
| Leonid Timashev | RBC Capital | Maintains | Outperform | $85.00 | - |
| Leonid Timashev | RBC Capital | Maintains | Outperform | $85.00 | - |
| Leonid Timashev | RBC Capital | Maintains | Outperform | $85.00 | - |
For valuable insights into Legend Biotech's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Legend Biotech analyst ratings.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Legend Biotech's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 187.57%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -182.24%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Legend Biotech's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -11.18%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Legend Biotech's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -7.85%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.26, Legend Biotech adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: LEGN
